Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

Helen J. MacKay; Douglas A. Levine; Victoria L. Bae-Jump; Daphne W. Bell; Jessica N. McAlpine; Alessandro Santin; Gini F. Fleming; David G. Mutch; Kenneth P. Nephew; Nicolas Wentzensen; Paul J. Goodfellow; Oliver Dorigo; Hans W. Nijman; Russell Broaddus; Elise C. Kohn

doi:10.18632/oncotarget.19961

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

Helen J. MacKay, Douglas A. Levine, Victoria L. Bae-Jump, Daphne W. Bell, Jessica N. McAlpine, Alessandro Santin, Gini F. Fleming, David G. Mutch, Kenneth P. Nephew, Nicolas Wentzensen, Paul J. Goodfellow, Oliver Dorigo, Hans W. Nijman, Russell Broaddus, Elise C. Kohn

Pathology

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

Original language	English (US)
Pages (from-to)	84579-84594
Number of pages	16
Journal	Oncotarget
Volume	8
Issue number	48
DOIs	https://doi.org/10.18632/oncotarget.19961
State	Published - 2017

Keywords

Endometrial cancer
Molecular targets

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.19961

Fingerprint

Dive into the research topics of 'Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials'. Together they form a unique fingerprint.

Cite this

MacKay, H. J., Levine, D. A., Bae-Jump, V. L., Bell, D. W., McAlpine, J. N., Santin, A., Fleming, G. F., Mutch, D. G., Nephew, K. P., Wentzensen, N., Goodfellow, P. J., Dorigo, O., Nijman, H. W., Broaddus, R., & Kohn, E. C. (2017). Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget, 8(48), 84579-84594. https://doi.org/10.18632/oncotarget.19961

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. / MacKay, Helen J.; Levine, Douglas A.; Bae-Jump, Victoria L. et al.
In: Oncotarget, Vol. 8, No. 48, 2017, p. 84579-84594.

Research output: Contribution to journal › Review article › peer-review

MacKay, HJ, Levine, DA, Bae-Jump, VL, Bell, DW, McAlpine, JN, Santin, A, Fleming, GF, Mutch, DG, Nephew, KP, Wentzensen, N, Goodfellow, PJ, Dorigo, O, Nijman, HW, Broaddus, R & Kohn, EC 2017, 'Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials', Oncotarget, vol. 8, no. 48, pp. 84579-84594. https://doi.org/10.18632/oncotarget.19961

@article{4980703f1d214ce096a8ea959951879c,

title = "Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials",

abstract = "The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.",

keywords = "Endometrial cancer, Molecular targets",

author = "MacKay, {Helen J.} and Levine, {Douglas A.} and Bae-Jump, {Victoria L.} and Bell, {Daphne W.} and McAlpine, {Jessica N.} and Alessandro Santin and Fleming, {Gini F.} and Mutch, {David G.} and Nephew, {Kenneth P.} and Nicolas Wentzensen and Goodfellow, {Paul J.} and Oliver Dorigo and Nijman, {Hans W.} and Russell Broaddus and Kohn, {Elise C.}",

note = "Publisher Copyright: {\textcopyright} MacKay et al.",

year = "2017",

doi = "10.18632/oncotarget.19961",

language = "English (US)",

volume = "8",

pages = "84579--84594",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "48",

}

TY - JOUR

T1 - Moving forward with actionable therapeutic targets and opportunities in endometrial cancer

T2 - NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

AU - MacKay, Helen J.

AU - Levine, Douglas A.

AU - Bae-Jump, Victoria L.

AU - Bell, Daphne W.

AU - McAlpine, Jessica N.

AU - Santin, Alessandro

AU - Fleming, Gini F.

AU - Mutch, David G.

AU - Nephew, Kenneth P.

AU - Wentzensen, Nicolas

AU - Goodfellow, Paul J.

AU - Dorigo, Oliver

AU - Nijman, Hans W.

AU - Broaddus, Russell

AU - Kohn, Elise C.

PY - 2017

Y1 - 2017

N2 - The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

AB - The incidence and mortality rates from endometrial cancer are increasing. There have been no new drugs approved for the treatment of endometrial cancer in decades. The National Cancer Institute, Gynecologic Cancer Steering Committee identified the integration of molecular and/or histologic stratification into endometrial cancer management as a top strategic priority. Based on this, they convened a group of experts to review the molecular data in this disease. Here we report on the actionable opportunities and therapeutic directions identified for incorporation into future clinical trials.

KW - Endometrial cancer

KW - Molecular targets

UR - http://www.scopus.com/inward/record.url?scp=85031044089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031044089&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19961

DO - 10.18632/oncotarget.19961

M3 - Review article

C2 - 29137450

AN - SCOPUS:85031044089

SN - 1949-2553

VL - 8

SP - 84579

EP - 84594

JO - Oncotarget

JF - Oncotarget

IS - 48

ER -

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this